|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 5. Inhibition of XNF-ATc3 signaling does not inhibit CE in the
mesoderm. Animal caps were treated as follows: (A) uninjected
control, (B) uninjected control treated with activin, (C)
injected with 250 pg CA XNF-ATc3 (CA) and treated with activin,
(D) injected with 500 pg CA XNF-ATc3 and treated with activin,
(E) injected with 1 ng DN XNF-ATc3 (DN) treated with activin,
and (F) treated with 400 nM CsA and activin. Injection of DN XNF-ATc3
did not inhibit CE even at concentrations of 4 ng DN XNF-ATc3. The
same was seen in animal caps treated with 4 mM CsA or 400 nM CsA plus FK506, a
calcineurin inhibitor that is know to show synergistic effects with CsA
(Flanagan et al., 1991;
Liu et al., 1991).
(G,H) DN XNF-ATc3 also failed to inhibit CE in Keller
explants overexpressing 2 ng DN XNF-ATc3 and 200 pg GFP. All
seven explants from two experiments elongated. (G) Bright-field of an
elongating Keller explant. (H) GFP fluorescence of G.
|
